CBD AUDIT 2018

In 2018 Dr Gulbransen started 400 patients on pure CBD (in grapeseed oil).

Patients were categorised as having:

- Pain
- Cancer symptoms
- Emotional Distress or
- Neurological Conditions.

- Pie charts show the outcome that patients reported after using CBD for one month.

- Removal of the ‘loss to follow up’ patients (those who did not see return to continue CBD because of cost, ineffectiveness, patient death (eg from cancer), etc) showing the most optimistic outcome. Many of these would likely be helped with the addition of THC and the full entourage.

- Unfortunately current Ministry of Health Regulations make products with over 2% THC unnecessarily complicated to access.
CBD Audit, 400 patients seen 2018

• Study design – follow up after using 25ml of CBD oil
• N=397
• Age 2 – 94
  • ⅓ age 40-59
  • ⅓ age 60-79
• Scale: NG – G – VG - E  250/397 = 63%
• QoL eq 109/397 = 28%
• QoL VAS 107/397 = 27%
N= 397, % Categories

- PAIN, 46%
- CANCER, 23%
- EMOTIONAL, 16%
- NEUROLOGICAL, 15%
PAIN (chronic) 181 patients

- Fibromyalgia
- Osteoarthritis
- Polymyalgia rheumatica
- Low back pain
- Neuropathic pain
- Central sensitisation
- Endometriosis
- Trigeminal neuralgia
- Inflammatory or irritable bowel pain
- Migraine etc.
CANCER SYMPTOMS 92 patients

• Often advanced with metastases
• Breast
• Bowel
• Prostate
• Lung
• Cervical
• Brain including glioblastoma multiforme (GBM)
• Melanoma etc.
EMOTIONAL DISTRESS 64 patients

• Anxiety/depression
• Insomnia
• ADHD
• Premenstrual syndrome (rages)
• Often comorbidities eg chronic pain, Tourettes, ASD.
NEUROLOGICAL SYMPTOMS 60 patients

- Seizures
- Autism spectrum with challenging behaviour, anxiety
- Parkinsons disease (with pain)
- Chronic fatigue
- Peripheral neuropathy
- Muscle spasms
- Multiple sclerosis
- Essential tremor etc.
PAIN N= 181, % Benefit

EXCELLENT: 13%
VERY GOOD: 17%
GOOD: 16%
NO BENEFIT: 23%
LOSS to Follow Up: 31%

Total: 30%
PAIN N= 125, % Benefit

- EXCELLENT: 19%
- VERY GOOD: 25%
- GOOD: 22%
- NO BENEFIT: 34%
CANCER SYMPTOMS N= 45, % Benefit

- EXCELLENT: 9%
- VERY GOOD: 12%
- GOOD: 14%
- NO BENEFIT: 14%
- LOSS to Follow Up: 51%

Total: 100%
CANCER SYMPTOMS N= 45, % Benefit

- Excellent: 19%
- Very Good: 24%
- Good: 28%
- No Benefit: 29%
EMOTIONAL DISTRESS N= 43, % Benefit

- EXCELLENT: 15%
- VERY GOOD: 18%
- GOOD: 26%
- NO BENEFIT: 11%
- LOSS to Follow Up: 30%

Other:
- 33%
EMOTIONAL DISTRESS N= 43, % Benefit

- EXCELLENT: 18%
- VERY GOOD: 27%
- GOOD: 39%
- NO BENEFIT: 16%
NEUROLOGICAL N= 37, % Benefit

- EXCELLENT: 5%
- VERY GOOD: 17%
- GOOD: 18%
- NO BENEFIT: 22%
- LOSS to Follow Up: 38%

22%
NEUROLOGICAL N= 37, % Benefit

- Excellent: 17%
- Very Good: 24%
- Good: 27%
- No Benefit: 32%